医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WNS Signs Contract Extension with Leading Pharmaceutical Company for High-End Research & Analytics Services 

2013年04月29日 PM07:55
このエントリーをはてなブックマークに追加


 

MUMBAI, India

WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Outsourcing (BPO) services, announced today that it has extended its contract with global pharmaceutical leader GlaxoSmithKline Services Unlimited (GSK), to deliver high-end research and analytics services.

“In a rapidly changing and increasingly competitive global economy, the ability to analyze large amounts of complex data to drive insight-based decisions is critical to success. WNS has been a trusted partner in delivering these high-value analytics solutions to GSK, and we are delighted to announce this contract extension with a recognized leader in the pharmaceutical industry,” said Keshav R. Murugesh, Group CEO, WNS Global Services.

WNS enables its global clients to make critical business decisions leveraging its research and analytics expertise, deep industry knowledge and robust delivery capabilities. WNS currently has over 2,000 research and analytics professionals supporting areas such as customer lifecycle analytics, market and business research, strategy and decision support, demand forecasting, customer risk scoring, loss management modeling, and measurement and reporting.

About WNS
WNS (Holdings) Limited (NYSE: WNS), is a leading global business process outsourcing company. WNS offers business value to 200+ global clients by combining operational excellence with deep domain expertise in key industry verticals including Travel, Insurance, Banking and Financial Services, Manufacturing, Retail and Consumer Packaged Goods, Shipping and Logistics and Healthcare and Utilities. WNS delivers an entire spectrum of business process outsourcing services such as finance and accounting, customer care, technology solutions, research and analytics and industry specific back office and front office processes. As of March 31, 2013, WNS had 25,520 professionals across 31 delivery centers worldwide including Costa Rica, India, Philippines, Poland, Romania, South Africa, Sri Lanka, United Kingdom and the United States. For more information, visit www.wns.com.

Safe Harbor Statement
This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 20-F and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT

WNS Global Services
Media Contact:
Sumi Gupta, Public
Relations
+91 (22) 4095 2263
sumi.gupta@wns.com
pr@wns.com
or
Investor
Contact:

David Mackey, Corporate SVP–Finance & Head of Investor
Relations
+1 201-942-6261
ir@wns.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent